
Glenmark Pharmaceuticals Ltd
Mumbai-based multinational pharmaceutical company founded in 1977, listed on the NSE and BSE, operating across generics, specialty and innovative medicines.
Company Type
public
Founded
1977
Headquarters
Mumbai, Maharashtra, India
Stock
NSE / BSE (532296): GLENMARK
Revenue
INR 169.8 billion (approximately $2.0 billion), FY2026 ended March 2026
Employees
Approximately 15,000
Primary Market
Global
Glenmark Pharmaceuticals Ltd Timeline
Shop Glenmark Pharmaceuticals Ltd Brands
Disclosure: We may earn commission from purchasesAbout Glenmark Pharmaceuticals Ltd
Who owns Glenmark Pharmaceuticals Ltd?
It is a publicly traded company on the NSE and BSE. The founding Saldanha family retains promoter control, with chairman Glenn Saldanha leading the company alongside institutional and public shareholders.
When was Glenmark founded?
Gracias Saldanha founded it in 1977 in Mumbai, naming it after his sons Glenn and Mark. It has been led by Glenn Saldanha as chairman and managing director.
What does Glenmark make?
Generic medicines for the US and global markets, branded formulations for India, and specialty products including the Ryaltris allergic rhinitis spray, across respiratory, dermatology, oncology and other therapy areas.
How large is Glenmark financially?
Consolidated revenue for fiscal 2026 (ended March 2026) was about 169.8 billion rupees, roughly $2 billion, up approximately 27.5 percent year over year, with around 15,000 employees.
Is Glenmark a generic or branded drug company?
Both. Generics provide the revenue base in the US and India, while specialty branded products like Ryaltris and an innovative pipeline represent its higher-margin strategy.
Where does Glenmark operate?
Headquartered in Mumbai with operations in more than 80 countries, major businesses in India and the US, manufacturing in India, and subsidiaries including Glenmark Pharmaceuticals Inc., USA and Glenmark Specialty SA.
History of Glenmark Pharmaceuticals Ltd
Gracias Saldanha founded Glenmark in 1977 in Mumbai, naming it after his two sons, Glenn and Mark. The company began as a domestic Indian pharmaceutical manufacturer and spent its first two decades building a formulations business in the Indian market.
International expansion defined the 1990s and 2000s. Glenmark entered the US generics market, established European operations and listed on Indian exchanges. Under Glenn Saldanha, who took over as chairman and managing director, the company pivoted from a pure generics manufacturer toward research-driven specialty and innovative medicines, investing heavily in its own R&D pipeline.
That strategy produced branded products that could compete beyond the generics price curve. Ryaltris, a fixed-dose olopatadine-mometasone nasal spray developed internally, won FDA approval in January 2022 and became the company's flagship branded respiratory product in the United States, with a pediatric label expansion to age six and up in July 2026.
Recent years also brought portfolio shaping. Glenmark has divested non-core assets to fund innovation, including selling a majority stake in its active pharmaceutical ingredient unit Glenmark Life Sciences, and has advanced novel oncology candidates. Fiscal 2026 revenue of about 169.8 billion rupees reflected the payoff from branded specialty growth and a strong US business.
Glenmark Pharmaceuticals Ltd Sustainability & Ethics
As a pharmaceutical manufacturer, Glenmark operates under drug safety, environmental and manufacturing compliance regimes across India, the US FDA, EMA and other regulators. Its facilities have periodically drawn FDA inspectional observations, a routine feature of Indian pharma operations in the US market.
The company publishes sustainability disclosures covering environmental management, access to medicines and community health programs in India. It has faced the industry-standard scrutiny applied to all Indian generic exporters on quality and pricing. No company-defining ethical crisis dominates its public record as of November 2026.
Brands Owned by Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd owns 1 brand in our database. Explore the ownership tree below — click categories to expand and see individual brands.
Glenmark Pharmaceuticals Ltd
public · Founded 1977 · Mumbai, Maharashtra, India
1
brands
Stock Information
Glenmark Pharmaceuticals Ltd Ownership: Pros & Cons
Advantages
- +Public listing provides transparent governance and capital access
- +Diversified revenue across Indian domestic, US generics and specialty
- +Proprietary products like Ryaltris deliver branded margins
- +Founder-family leadership provides strategic continuity since 1977
Considerations
- -US generics pricing erosion pressures a core revenue stream
- -Regulatory compliance demands across multiple jurisdictions
- -Innovation bets require sustained R&D spending against uncertain outcomes
- -Mid-size scale limits negotiating power versus global pharma giants
Frequently Asked Questions About Glenmark Pharmaceuticals Ltd
Who owns Glenmark Pharmaceuticals Ltd?
It is a publicly traded company on the NSE and BSE. The founding Saldanha family retains promoter control, with chairman Glenn Saldanha leading the company alongside institutional and public shareholders.
When was Glenmark founded?
Gracias Saldanha founded it in 1977 in Mumbai, naming it after his sons Glenn and Mark. It has been led by Glenn Saldanha as chairman and managing director.
What does Glenmark make?
Generic medicines for the US and global markets, branded formulations for India, and specialty products including the Ryaltris allergic rhinitis spray, across respiratory, dermatology, oncology and other therapy areas.
How large is Glenmark financially?
Consolidated revenue for fiscal 2026 (ended March 2026) was about 169.8 billion rupees, roughly $2 billion, up approximately 27.5 percent year over year, with around 15,000 employees.
Is Glenmark a generic or branded drug company?
Both. Generics provide the revenue base in the US and India, while specialty branded products like Ryaltris and an innovative pipeline represent its higher-margin strategy.
Where does Glenmark operate?
Headquartered in Mumbai with operations in more than 80 countries, major businesses in India and the US, manufacturing in India, and subsidiaries including Glenmark Pharmaceuticals Inc., USA and Glenmark Specialty SA.






